Alnylam to Webcast Presentations at Upcoming November Investor Conferences
Credit Suisse Healthcare Conferenceon Wednesday, November 8, 2017at 8:40 am MT( 10:40 am ET) at the Phoenician Hotelin Scottsdale, Arizona
Piper Jaffray Healthcare Conferenceon Wednesday, November 29, 2017at 8:30 am ETat the Lotte New York Palace Hotelin New York City
Evercore ISI BioPharma Catalyst/Deep Dive Conferenceon Wednesday, November 29, 2017at 9:30 am ETat the Boston Harbor Hotelin Boston
A live audio webcast of each presentation will be available on the Investors section of the Company's website, www.alnylam.com. A replay will be available on the Alnylam website within 48 hours after each event.
Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, and hepatic infectious diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust discovery platform and deep pipeline of investigational medicines, including four product candidates that are in late-stage development. Looking forward, Alnylam will continue to execute on its "Alnylam 2020" strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines to address the needs of patients who have limited or inadequate treatment options. Alnylam employs over 600 people in the
Investors and Media
News Provided by Acquire Media